Vistagen Plans Fiscal Year 2025 Second Quarter Results Update
Vistagen (NASDAQ: VTGN), a forward-thinking company in the clinical stage of developing products based on nose-to-brain neurocircuitry, has announced exciting plans for an upcoming conference call. The event is scheduled for November 7, 2024, providing a platform for the company to share its financial performance for the second quarter of fiscal year 2025, which concluded September 30, 2024. This event will also serve as an opportunity for Vistagen to offer a corporate update in an engaging format.
Details of the Conference Call
This informative conference call will occur at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Participants are encouraged to dial in using the toll-free number available for US participants, which is 1-800-717-1738, or use the international dial-in number at 1-646-307-1865. When calling in, please have the conference ID 1196845 ready to access the call easily.
How to Join the Webcast
Interested individuals can access the live audio webcast using the dedicated link provided for the event. It's advisable to log in about 10 minutes prior to the scheduled start to ensure a smooth experience. The audio from the conference call will also be recorded, allowing listeners to replay it after the live event shortly after 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time). The replay can be accessed using the toll-free number in the US, at 1-844-512-2921, or by calling the international line at 1-412-317-6671. Don’t forget to use the replay access ID number 1196845 during your call.
About Vistagen's Innovative Pipeline
Vistagen is a trailblazer in developing unique therapeutics designed to target the human brain without the need for systemic absorption. Their innovative product candidates, known as pherines, are specially formulated to activate the olfactory system and associated neurocircuitry in the brain. This action aims to produce therapeutic effects while maintaining a favorable safety profile.
Focused on Transformative Treatments
The company's robust pipeline reflects its commitment to address critical needs among patients who currently have limited treatment options. Vistagen's products are being targeted towards various mental health challenges, including social anxiety disorder and major depressive disorder, as well as addressing vasomotor symptoms experienced during menopause.
In addition to pherines, Vistagen is developing an oral prodrug known as AV-101, which targets the NMDA receptor and has potential applications in treating neurological conditions. The focus of the company is clear: to pioneer accessible, life-changing treatment solutions for prevalent and often debilitating disorders.
Looking Ahead
As Vistagen moves forward, the outcomes of the upcoming conference call and the insights shared will be closely watched by investors and stakeholders. The dedicated focus on neuroscience and patient-centric solutions underscore Vistagen's mission to enhance treatment pathways and ultimately improve patients' quality of life. With a promising pipeline and upcoming announcements, the future looks vibrant for Vistagen.
Frequently Asked Questions
What is the purpose of Vistagen's conference call?
The conference call aims to report the company's second quarter financial results for fiscal year 2025 and provide an update on corporate matters.
When is the scheduled date for the conference call?
The conference call is set for November 7, 2024, at 2:00 p.m. Pacific Time.
How can I participate in the conference call?
Participants can join the call using US and international dial-in numbers, and access the live audio webcast via a link provided by Vistagen.
What is Vistagen's main focus in its product development?
Vistagen is focused on developing intranasal product candidates designed to activate neurocircuitry for treating various mental health disorders.
Where is Vistagen headquartered?
Vistagen is headquartered in South San Francisco, California, focusing on innovative neuroscience-based therapeutic solutions.
